Synapsoft logo
AI Insights from Disclosures
Searching...
Celltrion, Inc. 068270
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Celltrion, Inc. has as its principal business the development and production of antibody drugs used to treat cancers, autoimmune diseases, and other conditions, based on biotechnology and mass animal cell culture technology. The company foresaw and prepared for the growth of the biosimilar business, and as a result obtained marketing authorization from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for Remsima (CT-P13), the world's first biosimilar product.
Representative Director Gi Useong, Seo Jinseok
Founded February 27, 1991
Corporation Type KOSPI
Industry Classification Manufacture of medicinal chemicals
Corporate number 13501-0034038
Business number 133-81-23603
Phone Number 032-850-5000
Fax Number 032-850-3486
Company Address 23 Academy-ro, Yeonsu-gu, Incheon
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant